Cenexi to manufacture OSE's COVID-19 vaccine

By The Science Advisory Board staff writers

June 30, 2021 -- Cenexi signed a deal agreeing to manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' COVID-19 vaccine candidate, which will be used in the product's development phases.

Under the deal, Cenexi will make and process the peptides, produce the sterile emulsion, and package clinical batches of the vaccine that is being used in the ongoing phase I clinical trial. The next-generation candidate is a multitarget, multivariant vaccine. The manufacturing will occur at Cenexi's site in Hérouville-Saint-Clair in Normandy, France. The site has a filling capacity of 40 million bottles annually.

Financial details of the agreement were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.